Close

Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance

Go back to Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance

Johnson & Johnson Reports Q3 2021 Results

October 19, 2021 6:25 AM EDT

NEW BRUNSWICK, N.J., Oct. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2021. "Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health," said Alex Gorsky, Chairman and Chief Executive Officer. "In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in... More